末梢性T細胞リンパ腫治療薬の世界市場:疫学予測

◆英語タイトル:Peripheral T-Cell Lymphoma Epidemiology Forecast to 2030
◆商品コード:DELV20JU213
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(213名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Peripheral T-Cell Lymphoma (PTCL)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted PTCL epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017–2030

Peripheral T-Cell Lymphoma (PTCL) Understanding
Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” It is PTCL’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.

PTCLs generally affects people aged 60 years and older and are diagnosed slightly more often in men than in women, however, younger adults and children are also diagnosed with PTCLs. PTCL is an uncommon disease in the United States, whereas some forms of PTCL are more common in Asia, Africa and the Caribbean, possibly as a result of exposure to specific viruses, such as the Epstein-Barr virus (EBV) and the human T-cell leukemia virus-1 (HTLV-1). PTCL comprises about 10–15% of all NHL cases in the United States. The World Health Organization (WHO) classification system recognizes subtypes of PTCL and has grouped the diseases into three categories: nodal, extranodal and leukemic. WHO has also divided T-cell lymphomas into two groups: aggressive (fast-growing) and indolent (slow-growing). PTCLs are a varied group of diseases that differ from B-cell lymphomas since PTCLs are less common than B-cell lymphomas, they are not as well understood.

Peripheral T-Cell Lymphoma (PTCL) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of PTCL, Stage-specific Incident Cases of PTCL, and Subtype-specific Cases of PTCL, a scenario of PTCL in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

PTCL Detailed Epidemiology Segmentation
The total incident population of PTCL in the seven major markets was 16,298 in 2017, which is expected to increase in the forecast period.
The United States accounted for the maximum incident population among the 7MM in 2017.
In EU5 countries, Germany accounted for the highest cases of PTCL while Spain had the lowest incident population in 2017.
The estimates suggest higher incidence of PTCL in the United States with 6,110 cases in 2017
The epidemiological model of DelveInsight estimates a higher proportion of PTCL cases was found in stage IV as compared to other stages in the United States. In 2017, stage I, stage II, stage III, and stage IV PTCL incident cases were 876, 727, 1,434, and 3,074 respectively.
PTCL-NOS accounts for 31% of all incident cases of PTCL followed by Anaplastic Large-Cell Lymphoma (ALCL) with 26% in the United States in year 2017. Other major subtypes include AITL Nasal NK/T-cell lymphoma, Enteropathy-type intestinal TCL, Hepatosplenic TCL and Others.
Scope of the Report
The report covers the descriptive overview of PTCL, explaining its causes, signs and symptoms, and pathophysiology.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The report assesses the disease risk and burden.
The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of PTCL, Stage-specific Incident Cases of PTCL, and Subtype-specific Incident Cases of PTCL.
Report Highlights
11-Year Forecast of PTCL
7MM Coverage
Incidence of PTCL in the 7MM
Stage-specific Incidence of PTCL in the 7MM
Subtype-specific Incidence of PTCL in the 7MM
Key Questions Answered
What is the disease risk, burden and unmet needs of PTCL?
What is the historical PTCL patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
What would be the forecasted patient pool of PTCL at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PTCL?
Out of the countries mentioned above, which country would have the highest incident population of PTCL during the forecast period (2020–2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)? 
Reasons to buy
The PTCL report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the 7MM PTCL market.
Quantify patient populations in the 7MM PTCL market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the specific type of PTCL that presents the best opportunities for PTCL therapeutics in each of the markets covered.
The PTCL epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
The PTCL epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of Peripheral T-cell Lymphoma (PTCL)

3. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)

3.1. Introduction

3.2. Classification of PTCL

3.2.1. WHO Classification System

3.3. Subtypes of PTCL

3.3.1. Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)

3.3.2. Anaplastic Large Cell Lymphoma (ALCL)

3.3.3. Angioimmunoblastic T-Cell Lymphoma (AITL)

3.4. Signs and Symptoms

3.5. Cause of PTCL

3.6. Pathophysiology

3.7. Other conditions that can mimic PTCL

3.8. Staging

3.9. Diagnosis

3.9.1. Blood tests

3.9.2. Diagnostic Scans

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. KOL Views

4.3. Epidemiology Methodology

4.4. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM

5. United States Epidemiology

5.1. Assumptions and Rationale

5.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States

5.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States

5.4. Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the United States

6. EU5 Epidemiology

6.1. Assumptions and Rationale

6.2. Germany Epidemiology

6.2.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany

6.2.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany

6.2.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany

6.3. France Epidemiology

6.3.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France

6.3.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France

6.3.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France

6.4. Italy Epidemiology

6.4.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy

6.4.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy

6.4.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy

6.5.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain

6.5.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain

6.5.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain

6.6. United Kingdom Epidemiology

6.6.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

6.6.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

6.6.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

7. Japan Epidemiology

7 .1. Assumptions and Rationale

7.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

7.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

7.4. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

8. Recognized Establishments

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Table 1 Summary of Peripheral T-cell Lymphoma (PTCL), Epidemiology and Key Events (2017–2030)

Table 2 Old and New WHO classifications of PTCLs

Table 3 Subtypes of PTCL

Table 4 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM (2017–2030)

Table 5 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)

Table 6 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)

Table 7 Subtype-specific Incident Cases of PTCL in the US (2017–2030)

Table 8 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)

Table 9 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)

Table 10 Subtype-specific Incident Cases of PTCL in Germany (2017–2030)

Table 11 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)

Table 12 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)

Table 13 Subtype-specific Incident Cases of PTCL in France (2017–2030)

Table 14 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)

Table 15 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)

Table 16 Subtype-specific Incident Cases of PTCL in Italy (2017–2030)

Table 17 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)

Table 18 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)

Table 19 Subtype-specific Incident Cases of PTCL in Spain (2017–2030)

Table 20 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)

Table 21 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)

Table 22 Subtype-specific Incident Cases of PTCL in the United Kingdom (2017–2030)

Table 23 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)

Table 24 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)

Table 25 Subtype-specific Incident Cases of PTCL in Japan (2017–2030)

List of Figures

Figure 1 Classification of PTCL

Figure 2 T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.

Figure 3 KOL Views

Figure 4 KOL Views

Figure 5 KOL Views

Figure 6 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM (2017–2030)

Figure 7 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)

Figure 8 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017–2030)

Figure 9 Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the US (2017–2030)

Figure 10 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)

Figure 11 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)

Figure 12 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017–2030)

Figure 13 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)

Figure 14 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)

Figure 15 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017–2030)

Figure 16 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)

Figure 17 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)

Figure 18 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017–2030)

Figure 19 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)

Figure 20 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)

Figure 21 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017–2030)

Figure 22 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)

Figure 23 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)

Figure 24 Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017–2030)

Figure 25 Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)

Figure 26 Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017–2030)

Figure 27 Subtype-specific Incident Cases of PTCL in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[末梢性T細胞リンパ腫治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆